Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer
Robert H Shoemaker, Reynold A Panettieri Jr, Steven K Libutti, Howard S Hochster, Norman R Watts, Paul T Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M White, Quentin Lawrence, Jeremy Boone, Jason D Marshall, Rebecca L Matthews, Brian D Cholewa, Jeffrey W Richig, Ben T Chen, David L McCormick, Romana Gugensberger, Sonja Höller, Josef M Penninger, Gerald Wirnsberger, Robert H Shoemaker, Reynold A Panettieri Jr, Steven K Libutti, Howard S Hochster, Norman R Watts, Paul T Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M White, Quentin Lawrence, Jeremy Boone, Jason D Marshall, Rebecca L Matthews, Brian D Cholewa, Jeffrey W Richig, Ben T Chen, David L McCormick, Romana Gugensberger, Sonja Höller, Josef M Penninger, Gerald Wirnsberger
Abstract
As ACE2 is the critical SARS-CoV-2 receptor, we hypothesized that aerosol administration of clinical grade soluble human recombinant ACE2 (APN01) will neutralize SARS-CoV-2 in the airways, limit spread of infection in the lung, and mitigate lung damage caused by deregulated signaling in the renin-angiotensin (RAS) and Kinin pathways. Here, after demonstrating in vitro neutralization of SARS-CoV-2 by APN01, and after obtaining preliminary evidence of its tolerability and preventive efficacy in a mouse model, we pursued development of an aerosol formulation. As a prerequisite to a clinical trial, we evaluated both virus binding activity and enzymatic activity for cleavage of Ang II following aerosolization. We report successful aerosolization for APN01, retaining viral binding as well as catalytic RAS activity. Dose range-finding and IND-enabling repeat-dose aerosol toxicology testing were conducted in dogs. Twice daily aerosol administration for two weeks at the maximum feasible concentration revealed no notable toxicities. Based on these results, a Phase I clinical trial in healthy volunteers has now been initiated (NCT05065645), with subsequent Phase II testing planned for individuals with SARS-CoV-2 infection.
Conflict of interest statement
Gerald Wirnsberger and Sonja Holler and Romana Gugensberger were employed by Apeiron Biologics A.G. Apeiron supplied the APN01 for study. Josef M. Pettinger was a founder of Apeiron, is a current shareholder and inventor of APN01. David L. McCormick is a Section Editor for PLOS One. Other authors declare no competing interests.
Figures
References
- Yan RH, Zhang YY, Li YN, Xia L, Guo YY, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448. doi: 10.1126/science.abb2762
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al.. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280. doi: 10.1016/j.cell.2020.02.052
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–292. doi: 10.1016/j.cell.2020.02.058
- Shang J, Ye G, Shi K, Wan YS, Luo CM, Aihara H, et al.. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224. doi: 10.1038/s41586-020-2179-y
- Wang QH, Zhang YF, Wu LL, Niu S, Song CL, Zhang ZY, et al.. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181(4):894–904. doi: 10.1016/j.cell.2020.03.045
- Wrapp D, Wang NS, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al.. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi: 10.1126/science.abb2507
- Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. Jama-J Am Med Assoc. 2021;325(13):1318–1320. doi: 10.1001/jama.2021.3199
- Linsky TW, Vergara R, Codina N, Nelson JW, Walker MJ, Su W, et al.. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science. 2020;370(6521):1208–1214. doi: 10.1126/science.abe0075
- Jiang SB, Hillyer C, Du LY. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020;41(5):355–359. doi: 10.1016/j.it.2020.03.007
- Wang YQ, Zhang L, Sang L, Ye F, Ruan SC, Zhong B, et al.. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235–5244. doi: 10.1172/JCI138759
- Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al.. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. New Engl J Med. 2021;384(3):238–251. doi: 10.1056/NEJMoa2035002
- Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, et al.. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. Embo Mol Med. 2021;13(1). doi: 10.15252/emmm.202013426
- Wirnsberger G, Monteil V, Eaton B, Postnikova E, Murphy M, Braunsfeld B, et al.. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. bioRxiv. 2021:2021.09.10.459744. doi: 10.1101/2021.09.10.459744
- Monteil V, Stephanie D, Klingström J, Thålin C, Kellner MJ, Christ W, et al.. Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections. bioRxiv. 2021:2021.12.25.474113.
- Kuba K, Imai Y, Rao SA, Gao H, Guo F, Guan B, et al.. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi: 10.1038/nm1267
- Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al.. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116. doi: 10.1038/nature03712
- Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al.. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21.
- Sims JJ, Greig JA, Michalson KT, Lian SR, Martino RA, Meggersee R, et al.. Intranasal gene therapy to prevent infection by SARS-CoV-2 variants. Plos Pathog. 2021;17(7). doi: 10.1371/journal.ppat.1009544
- Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, et al.. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181(4):905–913. doi: 10.1016/j.cell.2020.04.004
- Gawish R, Starkl P, Pimenov L, Hladik A, Lakovits K, Oberndorfer F, et al.. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFN gamma-driven immunopathology. Elife. 2022;11.
- Baazim H, Antonio-Herrera L, Bergthaler A. The interplay of immunology and cachexia in infection and cancer. Nat Rev Immunol. 2021:309–321. doi: 10.1038/s41577-021-00624-w
- DeGeorge JJ, Ahn CH, Andrews PA, Brower ME, Choi YS, Chun MY, et al.. Considerations for toxicology studies of respiratory drug products. Regul Toxicol Pharm. 1997;25(2):189–193. doi: 10.1006/rtph.1997.1099
- Zoufaly A, Poglitsch M, Aberle JH. Human recombinant soluble ACE2 in severe COVID-19 (vol 8, pg 1154, 2020). Lancet Resp Med. 2020;8(11):E78-E.
Source: PubMed